论文部分内容阅读
原发性眼内淋巴瘤是非何杰金淋巴瘤的一种不常见类型。累及玻璃体、视网膜或视网膜下间隙,也称眼内网状组织细胞肉瘤,免疫学标记研究证明是B细胞占优势的大细胞型的非何杰金淋巴瘤。本文6例眼内淋巴瘤的诊断是通过玻璃体穿刺活检(5例)或玻璃体摘除术(1例)而确立的。原发的眼内淋巴瘤用常规放疗后复发率高且发生中枢神经系统播散。化疗的效果常常令人失望,可能是因为血脑屏障使药物难以透入眼内之故。药物动力学研究证明特别是大剂量Ara-C静脉输注后能有效地进入脑脊液。本文作者采用大剂量静脉注射Ara-C治疗6例眼内淋巴瘤,其中4例以前未经治疗,1例以前曾接受过眼和中枢神经系统放射治疗而复发,还有1例因全身淋巴瘤以前接受过化疗。用Ara-C2000～3000mg/M~2静脉滴注1h以上,住院病例每
Primary intraocular lymphoma is an uncommon type of non-Hodgkin’s lymphoma. Involving the vitreous, the retina or subretinal space, also known as intraocular reticular tissue cell sarcoma, immunological markers proved to be the dominant B cell large non-Hodgkin’s lymphoma. The diagnosis of 6 cases of intraocular lymphoma was established by vitrectomy (5 cases) or vitrectomy (1 case). Primary intraocular lymphoma recurrence rate after conventional radiotherapy and the occurrence of central nervous system dissemination. The effects of chemotherapy are often disappointing, probably because the blood-brain barrier makes it harder for drugs to penetrate the eye. Pharmacokinetic studies have shown that, especially after high-dose Ara-C intravenous infusion can effectively enter the cerebrospinal fluid. The authors used high-dose intravenous Ara-C treatment of 6 cases of intra-ocular lymphoma, 4 of whom had previously been untreated, 1 of whom had previously received radiation from the CNS and relapsed, and 1 case of systemic lymphoma Have received chemotherapy. With Ara-C2000 ~ 3000mg / M ~ 2 intravenous infusion more than 1h, hospitalized cases per